184 related articles for article (PubMed ID: 16842248)
1. GLUT1 and p63 expression in endometrial intraepithelial and uterine serous papillary carcinoma.
Idrees MT; Schlosshauer P; Li G; Burstein DE
Histopathology; 2006 Jul; 49(1):75-81. PubMed ID: 16842248
[TBL] [Abstract][Full Text] [Related]
2. Immunodetection of GLUT1, p63 and phospho-histone H1 in invasive head and neck squamous carcinoma: correlation of immunohistochemical staining patterns with keratinization.
Burstein DE; Nagi C; Kohtz DS; Lee L; Wang B
Histopathology; 2006 May; 48(6):717-22. PubMed ID: 16681688
[TBL] [Abstract][Full Text] [Related]
3. p53 overexpression and bcl-2 persistence in endometrial carcinoma: comparison of papillary serous and endometrioid subtypes.
Zheng W; Cao P; Zheng M; Kramer EE; Godwin TA
Gynecol Oncol; 1996 May; 61(2):167-74. PubMed ID: 8626128
[TBL] [Abstract][Full Text] [Related]
4. Expression of the GLUT1 glucose transporter, p63 and p53 in thyroid carcinomas.
Kim YW; Do IG; Park YK
Pathol Res Pract; 2006; 202(11):759-65. PubMed ID: 17029809
[TBL] [Abstract][Full Text] [Related]
5. Human kallikrein 6: a new potential serum biomarker for uterine serous papillary cancer.
Santin AD; Diamandis EP; Bellone S; Soosaipillai A; Cane S; Palmieri M; Burnett A; Roman JJ; Pecorelli S
Clin Cancer Res; 2005 May; 11(9):3320-5. PubMed ID: 15867230
[TBL] [Abstract][Full Text] [Related]
6. Overexpression of claudin-3 and claudin-4 receptors in uterine serous papillary carcinoma: novel targets for a type-specific therapy using Clostridium perfringens enterotoxin (CPE).
Santin AD; Bellone S; Marizzoni M; Palmieri M; Siegel ER; McKenney JK; Hennings L; Comper F; Bandiera E; Pecorelli S
Cancer; 2007 Apr; 109(7):1312-22. PubMed ID: 17326053
[TBL] [Abstract][Full Text] [Related]
7. Endometrial glandular dysplasia: a newly defined precursor lesion of uterine papillary serous carcinoma. Part I: morphologic features.
Zheng W; Liang SX; Yu H; Rutherford T; Chambers SK; Schwartz PE
Int J Surg Pathol; 2004 Jul; 12(3):207-23. PubMed ID: 15306933
[TBL] [Abstract][Full Text] [Related]
8. Overexpression of HER-2/neu in uterine serous papillary cancer.
Santin AD; Bellone S; Gokden M; Palmieri M; Dunn D; Agha J; Roman JJ; Hutchins L; Pecorelli S; O'Brien T; Cannon MJ; Parham GP
Clin Cancer Res; 2002 May; 8(5):1271-9. PubMed ID: 12006548
[TBL] [Abstract][Full Text] [Related]
9. p53 protein overexpression: a strong prognostic factor in uterine papillary serous carcinoma.
Bancher-Todesca D; Gitsch G; Williams KE; Kohlberger P; Neunteufel W; Obermair A; Heinze G; Breitenecker G; Hacker NF
Gynecol Oncol; 1998 Oct; 71(1):59-63. PubMed ID: 9784320
[TBL] [Abstract][Full Text] [Related]
10. Determination of HER2/neu status in uterine serous papillary carcinoma: Comparative analysis of immunohistochemistry and fluorescence in situ hybridization.
Santin AD; Bellone S; Van Stedum S; Bushen W; De Las Casas LE; Korourian S; Tian E; Roman JJ; Burnett A; Pecorelli S
Gynecol Oncol; 2005 Jul; 98(1):24-30. PubMed ID: 15894362
[TBL] [Abstract][Full Text] [Related]
11. HMGA2 is commonly expressed in uterine serous carcinomas and is a useful adjunct to diagnosis.
McCluggage WG; Connolly LE; McBride HA; Kalloger S; Gilks CB
Histopathology; 2012 Mar; 60(4):547-53. PubMed ID: 22250726
[TBL] [Abstract][Full Text] [Related]
12. Serous papillary carcinoma of the endometrium arising from endometrial polyps: a clinical, histological, and immunohistochemical study of 13 cases.
Trahan S; Têtu B; Raymond PE
Hum Pathol; 2005 Dec; 36(12):1316-21. PubMed ID: 16311126
[TBL] [Abstract][Full Text] [Related]
13. High serum levels of interleukin-6 in endometrial carcinoma are associated with uterine serous papillary histology, a highly aggressive and chemotherapy-resistant variant of endometrial cancer.
Bellone S; Watts K; Cane' S; Palmieri M; Cannon MJ; Burnett A; Roman JJ; Pecorelli S; Santin AD
Gynecol Oncol; 2005 Jul; 98(1):92-8. PubMed ID: 15904949
[TBL] [Abstract][Full Text] [Related]
14. Postmenopausal status, hypertension and obesity as risk factors for malignant transformation in endometrial polyps.
Giordano G; Gnetti L; Merisio C; Melpignano M
Maturitas; 2007 Feb; 56(2):190-7. PubMed ID: 16963204
[TBL] [Abstract][Full Text] [Related]
15. MDM2 and p53 protein expression in the histologic subtypes of endometrial carcinoma.
Ambros RA; Sheehan CE; Kallakury BV; Ross JS; Malfetano J; Paunovich E; Figge J
Mod Pathol; 1996 Dec; 9(12):1165-9. PubMed ID: 8972476
[TBL] [Abstract][Full Text] [Related]
16. Expression of glucose transporter protein 1 and p63 in serous ovarian tumor.
Cai Y; Zhai JJ; Feng BB; Duan XZ; He XJ
J Obstet Gynaecol Res; 2014 Jul; 40(7):1925-30. PubMed ID: 25056472
[TBL] [Abstract][Full Text] [Related]
17. BCL-2 and P53 expression in endometrial carcinoma.
Erkanli S; Eren F; Pekin S; Bagis T
J Exp Clin Cancer Res; 2004 Mar; 23(1):97-103. PubMed ID: 15149157
[TBL] [Abstract][Full Text] [Related]
18. p53 in endometrial cancer and its putative precursors: evidence for diverse pathways of tumorigenesis.
Sherman ME; Bur ME; Kurman RJ
Hum Pathol; 1995 Nov; 26(11):1268-74. PubMed ID: 7590703
[TBL] [Abstract][Full Text] [Related]
19. Endometrial intraepithelial carcinoma: a case report and brief review.
Ram M; Bharadwaj M; Yadav R
Indian J Pathol Microbiol; 2008; 51(4):512-4. PubMed ID: 19008579
[TBL] [Abstract][Full Text] [Related]
20. Immunohistochemical detection of GLUT1, p63 and phosphorylated histone H1 in head and neck squamous intraepithelial neoplasia: evidence for aberrations in hypoxia-related, cell cycle- and stem-cell-regulatory pathways.
Burstein DE; Nagi C; Kohtz DS; Lumerman H; Wang BY
Histopathology; 2006 May; 48(6):708-16. PubMed ID: 16681687
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
